Inovio Pharmaceuticals
174 hedge funds and large institutions have $99.8M invested in Inovio Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 49 reducing their positions, and 30 closing their positions.
93% more call options, than puts
Call options by funds: $679K | Put options by funds: $351K
0.35% less ownership
Funds ownership: 4.25% → 3.9% (-0.35%)
2% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 49
5% less funds holding
Funds holding: 183 → 174 (-9)
17% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 30
49% less capital invested
Capital invested by funds: $197M → $99.8M (-$97.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.74M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.67M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.49M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.08M |
| 5 |
Citigroup
New York
|
+$966K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.73M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.06M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.63M |
| 4 |
Two Sigma Advisers
New York
|
-$1.83M |
| 5 |
Morgan Stanley
New York
|
-$1.05M |
INO Hedge Fund Activity: Q1 2023 in Review
174 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2023, worth a combined $99.8M — down 49% from $197M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of INO and 25 opened new positions — a net loss of 5 holders — while 49 trimmed existing stakes and 48 added.
The largest buyer was Vanguard Group, adding an estimated $1.74M. The largest seller was Millennium Management, exiting entirely with an estimated $6.73M sold.
- 174 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2023, down from 183 in Q4 2022.
- Funds reported $99.8M of Inovio Pharmaceuticals stock for Q1 2023, down 49% quarter-over-quarter.
- 25 funds opened new Inovio Pharmaceuticals positions in Q1 2023 and 30 closed out, a net change of -5 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2023 was Vanguard Group, an estimated $1.74M added.
- The largest Inovio Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $6.73M sold.
Based on aggregated 13F filings for Q1 2023.